CLDN4 and neoplasm: This was expected as oncogene-enriched subtype tumours exhibited more aggressive tumour growth and had an increased expression of gene mutations involved in cell proliferation (ERBB2, SLC44A4, EPCAM, CLDN3, and CLDN4), cell differentiation (ELF3 and GPX2), and mucin production (KRT20).